Related Experiment Videos
Reproduction toxicity studies with pamidronate
Arzneimittel-Forschung
|May 1, 1992
Summary
Pamidronate (disodium 3-amino-1-hydroxypropylidene-1,1-bisphosphonate pentahydrate) use in pregnancy is not advised due to risks of difficult labor and fetal skeletal issues, despite no teratogenic effects observed.
Area of Science:
- Pharmacology and Toxicology
- Reproductive Toxicology
- Developmental Toxicology
Background:
- Pamidronate is a bisphosphonate used to treat bone diseases.
- Understanding its reproductive and developmental toxicity is crucial for patient safety.
Purpose of the Study:
- To evaluate the reproductive and developmental toxicity of pamidronate in rats and rabbits.
- To assess the effects of both oral and intravenous administration routes.
Main Methods:
- Conducted Segment I, II, and III reproduction toxicity studies in rats and Segment II studies in rabbits.
- Administered pamidronate orally and intravenously.
- Monitored maternal toxicity, parturition, pup viability, and fetal development.
Main Results:
- Oral absorption of pamidronate was low (approximately 2%).
- Maternal toxicity, including parturition difficulties and reduced pup viability, was observed in rats at high doses.
- Fetal skeletal retardation and underdevelopment occurred in both species at doses ~10x human therapeutic levels.
- No teratogenic effects or impact on reproductive performance were noted.
Conclusions:
- Pamidronate use in pregnancy should be avoided due to potential adverse effects on parturition and fetal bone.
- The drug crosses the placenta and binds to fetal bone, necessitating caution.
- Use is only recommended when medically essential and no safer alternatives exist.